SCHEMBL20184015

SCHEMBL20184015

CC1(C)c2ccc(C#N)cc2C(=O)N1Cc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.48
MDM2 Q00987 7/20 0.46
CASP3 P42574 1/20 0.42
CA12 O43570 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CNR2 P34972 2/20 0.40
ABCB1 P08183 2/20 0.39
PGR P06401 1/20 0.39
BACE1 P56817 1/20 0.38
GABRA1 P14867 1/20 0.38
GABRG2 P18507 1/20 0.38
GABRB3 P28472 1/20 0.38
GABRA5 P31644 1/20 0.38
GABRA3 P34903 1/20 0.38
GABRA2 P47869 1/20 0.38
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2027394 0.79 ALDH1A1 (0.72) ALDH1A1MDM2TP53
SCHEMBL22939236 0.77 CASP3 (0.42) ALDH1A1MDM2CASP3PGRBACE1
SCHEMBL14991909 0.76 MDM2 (0.43) ALDH1A1MDM2
SCHEMBL22939076 0.75 CASP3 (0.50) CASP3ABCB1PGRGABRA1GABRG2
SCHEMBL20184098 0.71 HDAC1 (0.52) CA12CA2CA9
SCHEMBL20100137 0.68 MDM2 (0.72) ALDH1A1MDM2PGRTP53
SCHEMBL7281529 0.68 CA12 (0.72) CA12CA2CA9TDP1
SCHEMBL31411889 0.68 PGR (0.50) ALDH1A1TDP1PGRBACE1TP53
SCHEMBL20184067 0.67 HDAC6 (0.48)
SCHEMBL7364966 0.67 L3MBTL1 (0.47) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10357484-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-07-23 US disclosed
US-20190008836-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-01-10 US disclosed
EP-3327019-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2018-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10357484-B2 Heterocyclic compound HDAC1, HDAC11, HDAC5 ALDH1A1 696/4885MDM2 4012/4885CASP3 344/4885
US-20190008836-A1 HETEROCYCLIC COMPOUND HDAC1, HDAC11, HDAC5 ALDH1A1 696/4885MDM2 4012/4885CASP3 344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.